Literature DB >> 6255549

An evaluation of two years of clinical experience with ketoconazole.

J Symoens, M Moens, J Dom, H Scheijgrond, J Dony, V Schuermans, R Legendre, N Finestine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6255549     DOI： 10.1093/clinids/2.4.674

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


× No keyword cloud information.
  20 in total

1.  Enilconazole as an adjunct to the treatment of four cases of canine nasal aspergillosis.

Authors:  T Lanthier; A Chalifoux
Journal:  Can Vet J       Date:  1991-02       Impact factor: 1.008

2.  Dermatology-important advances in clinical medicine: ketoconazole.

Authors:  P H Jacobs
Journal:  West J Med       Date:  1983-06

3.  Toxic hepatis during ketoconazole treatment.

Authors:  J K Heiberg; E Svejgaard
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-26

4.  Susceptibility of zygomycetes to amphotericin B, miconazole, and ketoconazole.

Authors:  R H Eng; A Person; C Mangura; H Chmel; M Corrado
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

5.  Ketoconazole impairs biliary excretory function in the isolated perfused rat liver.

Authors:  G B Gaeta; M F Tripodi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

6.  Hematogenous Candida vertebral osteomyelitis treated with ketoconazole.

Authors:  B A Dijkmans; M I Koolen; R P Mouton; T H Falke; P J van den Broek; J W van der Meer
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

Review 7.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

8.  Distribution of oral ketoconazole to vaginal tissue.

Authors:  J J Heykants; R J Woestenborghs; M P Bisschop; J M Merkus
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

Review 9.  Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Authors:  Cara H Nelson; Brian R Buttrick; Nina Isoherranen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.

Authors:  R Guinet; D Nerson; F de Closets; J Dupouy-Camet; L Kures; M Marjollet; J L Poirot; A Ros; J Texier-Maugein; P J Volle
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.